The Maldives Food and Drug Authority (MFDA) issued a statement in response to a recent alert from the World Health Organization (WHO), cautioning about the presence of chemical substances, including diethylene glycol and ethylene glycol, in a medicine used to treat cough and fever since October 2022.
As a precautionary measure, the Maldives has initiated random sampling and screening of the affected medicine. Due to the complexity of the testing required, these samples have been sent abroad for comprehensive analysis.
To date, 10 samples have been collected and examined in the market, revealing the presence of these chemical contaminants in the B220 batch of cetirizine manufactured by Pakistan’s Pharmix Laboratory. The MFDA has confirmed this alarming discovery.
In light of these findings, the MFDA has taken decisive action by prohibiting the import, sale, and use of the affected brand. This prohibition will remain in effect until test results are obtained, and the safety and purity of the medicine are conclusively ensured.
The MFDA, in line with its commitment to safeguarding public health, emphasizes the importance of strict adherence to these precautionary measures. The health and well-being of Maldivian citizens remain paramount, and the MFDA will closely monitor and provide further updates regarding this situation as it unfolds.